Patent intelligence · US
US 11628215
HIV vaccines comprising one or more population episensus antigens
HIV vaccines comprising one or more population episensus antigens
Patent details — US 11628215
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 18, 2023
- Expiration
- Apr 13, 2043
- Applicant
- Vir Biotechnology, Inc.
- Claims
- 7
- CPC classes
- A61K, A61K2039/53, A61K2039/70, A61K39/12
Quick answer
US 11628215 (HIV vaccines comprising one or more population episensus antigens) is held by Vir Biotechnology, Inc.. Status: granted. Granted Apr 18, 2023. Expires Apr 13, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Vir Biotechnology, Inc.
- Grant date
- Expiration
- Claims
- 7
- CPC classes
- A61K, A61K2039/53, A61K2039/70, A61K39/12, A61K39/21, A61P
More from Vir Biotechnology, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12404318
Combination HBV therapy
granted -
US 11554168
HIV vaccines comprising one or more population episensus antigens
granted -
US 11479599
Antibodies against SARS-CoV-2 and methods of using the same
granted -
US 11168128
Antibodies against SARS-CoV-2 and methods of using the same
granted -
US 10894078
HIV vaccines comprising one or more population episensus antigens
granted
Frequently asked questions
What is US patent 11628215?
US 11628215 (HIV vaccines comprising one or more population episensus antigens) is held by Vir Biotechnology, Inc.. Status: granted. Granted Apr 18, 2023. Expires Apr 13, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11628215?
Vir Biotechnology, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 6 pharmaceutical patents for this assignee.
When does US 11628215 expire?
Our index shows an expiration date of Apr 13, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.